Khan Mohammad Ashrafuddin, El-Gamal Mohammed I, Oh Chang-Hyun
Center for Biomaterials, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, Korea.
Mini Rev Med Chem. 2017;17(4):351-365. doi: 10.2174/1389557516666160622213142.
B-RAF gene is a component of the MAPK pathway that plays a very important role in cell division, survival, proliferation, and many other cellular functions. Mutations of the B-RAF (such as V600E-B-RAF) lead to melanoma, which is one of the leading causes of death worldwide. R&D progress is being done aiming at improved therapy in the future. The existing melanoma therapy is left out with poor overall survival, drug resistance, and many side effects. With the recent approval of new drugs, there is a hope for melanoma patients for complete cure and better life quality. However, there is still a need for improved, safe, and complete therapy for advanced melanoma. This review describes melanoma caused by V600E-B-RAF gene mutation, its pathway, drugs available and recently approved drugs, and future prospects to be overcome.
B-RAF基因是丝裂原活化蛋白激酶（MAPK）信号通路的一个组成部分，在细胞分裂、存活、增殖以及许多其他细胞功能中发挥着非常重要的作用。B-RAF基因的突变（如V600E-B-RAF）会导致黑色素瘤，而黑色素瘤是全球主要的死亡原因之一。目前正在进行研发工作，旨在未来改善治疗方法。现有的黑色素瘤治疗方法存在总体生存率低、耐药性以及许多副作用等问题。随着近期新药的获批，黑色素瘤患者有望实现完全治愈并提高生活质量。然而，对于晚期黑色素瘤，仍需要改进、安全且彻底的治疗方法。本综述描述了由V600E-B-RAF基因突变引起的黑色素瘤、其信号通路、现有药物和近期获批的药物，以及有待攻克的未来前景。
